AI Verdict
RAMP has stronger fundamentals based on our AI analysis.
RARE vs RAMP Fundamental Comparison
| Metric | RARE | RAMP |
|---|---|---|
| Revenue | $673.0M | $606.8M |
| Net Income | $-575.0M | $75.0M |
| Net Margin | -85.4% | 12.4% |
| ROE | N/A | 7.8% |
| ROA | -37.5% | 5.9% |
| Current Ratio | 2.48x | 2.72x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-5.83 | $1.14 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RARE vs RAMP: Frequently Asked Questions
Is RARE or RAMP a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RAMP has stronger fundamentals. RARE is rated SELL (72% confidence) while RAMP is rated HOLD (58% confidence). This is not investment advice.
How does RARE compare to RAMP fundamentally?
Ultragenyx Pharmaceutical Inc. has ROE of N/A vs LiveRamp Holdings, Inc.'s 7.8%. Net margins are -85.4% vs 12.4% respectively.
Which stock pays higher dividends, RARE or RAMP?
RARE has a dividend yield of N/A or no dividend while RAMP has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RARE or RAMP for long term?
For long-term investing, consider that RARE has SELL rating with 72% confidence, while RAMP has HOLD rating with 58% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RARE vs RAMP?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RARE vs RAMP, the AI consensus favors RAMP based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.